Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

431
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
431
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

576
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
576
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.5K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.5K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Immediate Implant Placement With Guided Bone Regeneration in Compromised Anterior Maxillary Sites: Aesthetic Outcomes.

Clinical case reports·2026
Same journal

Post-Thrombotic Syndrome of Lower Extremity.

Clinical case reports·2026
Same journal

Age-Adjusted AFP Interpretation in Neonatal Sacrococcygeal Teratoma: Why Adult Reference Ranges May Mislead.

Clinical case reports·2026
Same journal

Prenatal Fetal Growth Restriction and Cardiomyopathy Associated With an Unbalanced der(15)t(7;15): A Case Report.

Clinical case reports·2026
Same journal

Coexisting Pyogenic and Tuberculous Liver Abscess in Uncontrolled Diabetes: A Diagnostic Challenge.

Clinical case reports·2026
Same journal

A Simple Scope-Advancement Technique to Correct Pancreatic-Biliary Duct Axis Misalignment During Pancreatic Guidewire-Assisted Biliary Cannulation.

Clinical case reports·2026

Related Experiment Video

Updated: Mar 6, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

Case report: apixaban-induced thrombocytopenia.

Oliver Snellgrove1

  • 1Intensive Care Unit Hornsby Hospital Hornsby New South Wales Australia.

Clinical Case Reports
|March 8, 2017
PubMed
Summary

Apixaban, a new anticoagulant, can rarely cause life-threatening thrombocytopenia. Clinicians should monitor patients closely for this adverse event, especially those with Heparin-Induced Thrombocytopenia (HIT).

Area of Science:

  • Pharmacology
  • Hematology
  • Clinical Medicine

Background:

  • Apixaban is a novel oral anticoagulant with an evolving safety profile.
  • Thrombocytopenia is a rare but serious adverse effect associated with anticoagulant therapy.

Observation:

  • This report details an uncommon, life-threatening case of thrombocytopenia potentially linked to apixaban use.
  • No prior published case reports specifically document apixaban-induced thrombocytopenia.

Findings:

  • The study highlights a critical safety concern regarding apixaban.
  • Awareness of this potential side effect is crucial for clinical practice.

Implications:

  • Clinicians must exercise caution and monitor for thrombocytopenia in patients on apixaban.
Keywords:
Apixabanthrombocytopenia

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.7K

Related Experiment Videos

Last Updated: Mar 6, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.7K
  • Further research is warranted, particularly regarding apixaban's role in managing Heparin-Induced Thrombocytopenia (HIT).